HIV/AIDS Medications: Research on Isentress (Raltegravir)
- Study Summaries From ICAAC 2012 (September/October 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Raltegravir Shows Long-Term Safety and Efficacy for HIV/HCV and HIV/HBV Coinfection (September 20, 2012)
From HIVandHepatitis.com
- Skeletal Muscle Toxicity and Raltegravir (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Dolutegravir vs. Raltegravir in Treatment-Naive Patients: 48-Week Results From the SPRING 2 Study (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Elvitegravir vs. Raltegravir: 96-Week Phase III Results in Treatment-Experienced Patients (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Five-Year Results From Raltegravir Registrational Studies (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Raltegravir Remains Effective and Well-Tolerated at 5 Years (August 7, 2012)
From HIVandHepatitis.com
- Gilead HIV Drug as Good as Merck's Isentress: Study (August 2, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
On TheBodyPRO.com
- AIDS 2012: Other Treatment Studies (August 1, 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- Raltegravir 800 mg Twice Daily Appears a Good Alternative to Efavirenz for HIV-TB Treatment (July 31, 2012)
From aidsmap.com
VIEW ALL ARTICLES
|
Advertisement
|
Email
Glossary
